The NF-B family of transcription factors regulates a diverse range of cellular responses including cell proliferation, differentiation, programmed cell death, immune response, and tumorigenesis (1, 2). NF-B transcription factor includes five subunits (p65 (Rel A), p50/p105 (NFB1), p52/p100 (NFB2), c-Rel, and Rel B), and its activity is controlled by inhibitor protein IB␣ (3). These proteins share sequence similarity over an ϳ300-amino acid Rel homology domain, forming transcription factor complexes with a wide range of DNA binding and activation potential (4). Under normal endogenous conditions, NF-B subunits reside in the cytoplasm in an inactive form bound to IB family proteins. Upon activation by various stimuli, IB family proteins get phosphorylated by IB kinase (IKK) 4 complex and undergo proteosomal degradation thereby allowing nuclear translocation and accumulation of functional NF-B complexes (5-7). In the nucleus, NF-B transcription factor promotes the expression of over 150 target genes that are involved in the host immune response and in various physiological stress conditions (1). Thus, NF-B/Rel regulatory proteins influence important cell fate decisions and are activated in a range of conditions involving cellular stress and injury.
The NF-B family of transcription factors regulates a diverse range of cellular responses including cell proliferation, differentiation, programmed cell death, immune response, and tumorigenesis (1, 2) . NF-B transcription factor includes five subunits (p65 (Rel A), p50/p105 (NFB1), p52/p100 (NFB2), c-Rel, and Rel B), and its activity is controlled by inhibitor protein IB␣ (3) . These proteins share sequence similarity over an ϳ300-amino acid Rel homology domain, forming transcription factor complexes with a wide range of DNA binding and activation potential (4) . Under normal endogenous conditions, NF-B subunits reside in the cytoplasm in an inactive form bound to IB family proteins. Upon activation by various stimuli, IB family proteins get phosphorylated by IB kinase (IKK) 4 complex and undergo proteosomal degradation thereby allowing nuclear translocation and accumulation of functional NF-B complexes (5) (6) (7) . In the nucleus, NF-B transcription factor promotes the expression of over 150 target genes that are involved in the host immune response and in various physiological stress conditions (1) . Thus, NF-B/Rel regulatory proteins influence important cell fate decisions and are activated in a range of conditions involving cellular stress and injury. Based on the stimulus and the molecules involved in the NF-B signaling module, NF-B activation pathways are classified as canonical and non-canonical. Although the canonical pathway is induced largely by IKK␤ and utilizes three canonical IB proteins (IB␣, IB␤, and IB⑀), the non-canonical pathway requires IKK␣, which induces partial degradation of p100/Rel B to p52/Rel B (8) . In addition, there are alternative pathways for NF-B activation that involve NF-B-inducing kinase and IKK⑀ (9, 10) . Another pathway involving DNA damage activates NF-B via the atypical pathway (11) (12) (13) . However, the kinetics of NF-B activation through the atypical pathway is relatively slower compared with canonical and non-canonical pathways.
Activation of NF-B by various stimuli including inflammatory cytokines, phorbol esters, bacterial toxins, viruses, and mitogens promotes initiation, development, and maintenance of tumors (14, 15) . NF-B-mediated angiogenesis and development of resistance to apoptosis induced by chemotherapy is thought to be the major contribution in its role during tumor development (16) . In this regard, NF-B has been reported to promote both angiogenesis and metastasis in certain tumor models through regulation of vascular endothelial growth factor and matrix metalloproteinases (17, 18) . Additionally NF-B can promote cellular proliferation by activating Cyclin D1 promoter through Rb hyperphosphorylation (19, 20) . Thus, inhibi-tion of NF-B activity is considered a potential therapy to target cancer (21, 22) . Although the tumor-promoting function of NF-B is well studied, there are reports suggesting that NF-B activity is not always tumorigenic (23, 24) . Mouse embryonic fibroblasts lacking p65 expression showed a malignant transformed phenotype (25) . Another report showed that inhibiting NF-B activity leads to induction of Ras-mediated squamous cell carcinoma (26) . NF-B is also reported to induce promoter activity of tumor suppressor p53 in response to tumor necrosis factor ␣ (TNF␣), and p53 in turn induces the association of p52 (NF-B2) with HDAC1 and represses Cyclin D1 transcription (27) . Tumor suppressor protein ARF has also been shown to inhibit the transactivation function of NF-B independently of p53-mdm2 function. Moreover inhibition of p65-mediated transcription by tumor suppressor ING4 in gliomas provides further evidence that NF-B activity can be modulated by its association with various tumor suppressor proteins (28, 29) . These findings suggest that the tumor-promoting functions of NF-B can be regulated by tumor suppressor proteins.
Matrix attachment region (MAR)-binding proteins organize chromatin in loop domain structure thereby partitioning chromatin from actively transcribing regions to poorly transcribing regions (30, 31) . This is brought about by their interactions with a plethora of chromatin-modifying proteins that dictate signature histone patterns governing gene transcription. As such dysregulation of various MAR-binding proteins is often seen as a major event during transition of cells to tumorigenesis, which involves chromatin rearrangements and aberrant activation of different sets of gene programs (32, 33) . SMAR1 is a MARbinding protein, and its role in tumor suppression has been highlighted recently. SMAR1 originally identified in mouse thymocyte regulates V(D)J recombination and is known to repress E␤-mediated transcription at the TCR␤ locus via its interaction with Cux (34 -36) . Moreover SMAR1 interacts with HDAC1-associated repressor complex at Cyclin D1 promoter and allows histone deacetylation and transcriptional repression (37) . SMAR1 also inhibits tumor growth through p53 stabilization and cell cycle arrest (38) . Further SMAR1-derived p44 peptide has been shown to actively inhibit tumor growth in vivo (39) . Recently we have shown that SMAR1 is up-regulated upon doxorubicin treatment in a p53-dependent manner. p53 directly binds to its response element present in SMAR1 promoter and recruits activator complex that induce SMAR1 transcription. Further we demonstrated that SMAR1 is down-regulated in advanced stages of human breast cancer, and its overexpression in breast cancer cell lines inhibits their metastatic potential through modulation of transforming growth factor ␤ signaling (40) . Because both SMAR1 and NF-B play important role in cancers, here we investigated their coordinated role in tumorigenesis.
In this study, we report that induction of tumor suppressor protein SMAR1 by doxorubicin or overexpression induces the formation of functional NF-B complexes through direct regulation of IB␣ transcription. SMAR1 binds to the MAR present in IB␣ promoter, recruits HDAC1, forms a repressor complex together with p65/p50 at the locus, and thus inhibits transcription. In contrast, SMAR1 inhibited TNF␣-mediated activation of NF-B. Real time PCR array revealed that SMAR1 represses a set of B target genes that promote tumorigenesis. Inversely knockdown of SMAR1 by specific siRNAs resulted in direct induction of these genes, which were further induced in the presence of TNF␣. Thus, we show that NF-B activity and SMAR1 expression are directly and functionally co-related. In brief, SMAR1 modulates NF-B transactivation and regulates the expression of NF-B target genes through its interaction with MARs.
EXPERIMENTAL PROCEDURES
Cell Culture, Condition, and Reagents-Breast cancer cell line MCF-7, mouse melanoma cell line B16F1, and SMAR1 stable B16F1 cells (41) were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 unit/ml penicillin, and 100 g/ml streptomycin (Invitrogen). Doxorubicin and human recombinant TNF␣ were obtained from Sigma. Cells were plated at a density of 2 ϫ 10 6 /well and treated with 0.5-2.0 M doxorubicin for 24 h, 10 ng/ml TNF␣ for 2 h, and 10 nM NF-B inhibitor (Calbiochem) for 30 min either alone or in combination.
Transfections, Plasmid Constructs, and Recombinant SMAR1 Adenovirus-All transfections were done using Lipofectamine 2000 (Invitrogen). SMAR1 expression plasmid pBK-CMV-SMAR1 (36) and recombinant adenovirus-generated SMAR1 (38) were used for overexpression studies. The 1.9-kb SMAR1 cDNA was cloned in pAdTrack-CMV vector followed by homologous recombination with pAdEasy vector in BJ5183 strain of Escherichia coli. The recombinant clones were screened for insert, linearized with PacI (New England Biolabs and transfected into HEK293 cells for packaging of virus. The virus thus produced was amplified, titrated, and further used for overexpression studies. For knockdown studies, siRNA specific for SMAR1 and control scrambled siRNA (Ambion) were used as described before (42) . For generation of the SMAR1 shRNA construct, 22-mer double-stranded oligo derived from SMAR1 mRNA sequence was cloned in RNA interference retroviral vector pSIREN-RetroQ (Clontech).
IB␣ Promoter Cloning-The 750-bp fragment of IB␣ gene promoter was PCR-amplified and ligated to the pGMTeasy vector, subcloned in pSP73 vector (Promega) in EcoRI site, and finally cloned into pGL3 basic reporter vector (Promega) using BglII and KpnI sites. Orientation of the sense clones were checked by using HindIII site at the 5Ј region of the IB␣ gene promoter.
Luciferase Reporter Assay-MCF-7 cells were transiently transfected with 1 g of pGL3-IB␣ (750-bp) constructs along with 0.5 g of pEGFP vector for internal controls. Cells were harvested 24 h post-transfection, lysed in Luclite reagent (PerkinElmer Life Sciences). Luciferase counts were measured using a TopCount luminometer (PerkinElmer Life Sciences). Transfection efficiency was normalized to GFP counts measured using a Fluoroskan Ascent Luminometer (Lab Systems). All assays were done in triplicates.
Real Time PCR-MCF-7 cells (1 ϫ 10 6 ) transfected with pBK-CMV-SMAR1 (1.0 g for 36 h) or treated with doxorubicin (0.5 M for 24 h) were processed for total RNA isolation and cDNA synthesis following the manufacturer's instructions (Invitrogen). Real time reverse transcription-PCR was per-formed by an iCycler iQ thermal cycler system (Bio-Rad) using the double-stranded DNA-specific fluorophore SYBR Green. In a 25-l PCR, 1 l of cDNA was amplified using SYBR Green Supermix (Bio-Rad) containing 0.4 mM deoxynucleoside triphosphate mixture, 1.5 mM MgCl 2 , 50 pmol of a forward and reverse primer mixture, SYBR Green I, and 0.5 units of iTaq DNA polymerase. PCR was done using primers specific for IB␣, SMAR1, and ␤-actin. Resolution of the product of interest from nonspecific product amplification was achieved by melt curve analysis. Confirmation of a single product was checked by agarose gel analysis. Quantification was performed with three different sets of cDNA samples. Graphs were plotted, and statistical analysis was performed using SigmaPlot. Sequences of primers used are given in supplemental Table 1 .
Immunoblotting and Antibodies-Cells were scraped, washed with 1ϫ phosphate-buffered saline (PBS) at different time intervals, and lysed in modified DIGNAM buffer (50 mM Tris, pH 7.5, 120 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM dithiothreitol, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, and 0.5 mg/ml protease inhibitor). Cells were then centrifuged for 10 min at 10,000 ϫ g, and insoluble debris were discarded. Protein concentrations were estimated using Bradford reagent (Bio-Rad). An equal amount of protein was loaded for immunoblotting. Following SDS-polyacrylamide gel electrophoresis, resolved proteins were electroblotted on a polyvinylidene difluoride membrane (Amersham Biosciences). The membrane was blocked overnight in Tris-buffered saline containing 0.1% Tween 20 (TBST) and 5% bovine serum albumin. The membrane was then probed with primary antibody in TBST for 2 h followed by three 10-min TBST washes at room temperature. Incubation with the secondary antibody was done for 1 h, and three 10-min TBST washes were done prior to detection. Proteins were detected using enhanced chemiluminescence substrate (Amersham Biosciences). Antibodies for p50, IB␣, ␤-actin, and horseradish peroxidase-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology. p65 NF-B and phosphoserine 536 p65 NF-B were obtained from Cell Signaling Technology. Rabbit polyclonal SMAR1 antibody was raised in house. For this GST-SMAR1 (400 -548 amino acids) conjugated with appropriate adjuvant was injected in the rabbit. Following three booster doses, the antibody titer was checked, and the ascitic fluid was further purified using recombinant protein A beads (Sigma).
Confocal Microscopy-B16F1 or MCF-7 cells were plated at 2 ϫ 10 5 /ml on coverslips in 35-mm culture dishes. After 24 h, MCF-7 cells were transfected with 1.0 g of pEGFPC3-SMAR1 plasmid. Coverslips were removed after 48 h and processed for confocal microscopy. Cells were fixed with 2.0% paraformaldehyde for 15 min at room temperature followed by permeabilization with 0.1% Triton X-100 in PBS for 5 min and blocked in 10% fetal bovine serum in PBS for 1 h. Fluorescein isothiocyanate-conjugated anti-goat (Santa Cruz Biotechnology) and Cy3-conjugated anti-mouse (Amersham Biosciences) secondary antibodies were used at a 1:200 and 1:400 dilutions, respectively. When indicated, specimens were analyzed with a confocal laser microscope (LSM 510, version 2.01; Zeiss, Thornwood, NY). Image analysis and quantification of immunostaining was done using LSM 510 version 2.01 software (Ziess). For quantification at least 50 cells were observed from five different fields, and the mean fluorescence intensity was measured. Statistical analysis was done using SigmaPlot.
Purification of GST Fusion Proteins-For SMAR1 protein purification, GST-SMAR1 clones were grown in Luria-Bertani medium with ampicillin and induced with 1 mM isopropyl ␤-Dthiogalactopyranoside. Cells were resuspended in lysis buffer containing PBS, Triton X-100, 1% Sarkosyl (Sigma), and protease inhibitors (Roche Applied Science). After sonication, the supernatant was incubated with glutathione-Sepharose beads (Amersham Biosciences) for 1 h at 4°C with gentle agitation. After three washes, each with lysis buffer and PBS, the protein was eluted with 100 mM reduced glutathione buffer. The eluted fraction was resolved on gels, and protein bands were visualized by Coomassie staining.
Electrophoretic Mobility Shift Assay-The 200-bp fragment of IB␣ promoter spanning the putative MAR was amplified using primer 401F-610R and was used as Probe I. Another region of 260 bp (non-MAR) was amplified using primer 881F-1141R and was used as negative control. A 50-mer MAR oligo (Probe II), mutant IB␣ MAR oligos (Probe III, Probe IV, and Probe V), NF-B consensus oligo, and NF-B mutant oligo were chemically synthesized (Genomechanix). All the primers and oligo sequences used in PCR are provided in supplemental Table 1 . Nuclear lysate were prepared using modified DIGNAM buffer as described in Ref. 34 . Oligonucleotide labeling was done by a Klenow reaction using [␣- 32 P]dCTP in a 20-l reaction containing 1 mM dNTP mixture, Klenow buffer, and 0.5 units of Klenow fragment (New England Biolabs). Probe purification was done using a Probequant G-50 column (Amersham Biosciences). Nuclear lysates (5-10 g) were incubated with respective probes in a 10-l total volume containing binding buffer (10 mM HEPES, pH 7.5, 50 mM KCl, 1 mM dithiothreitol, 10% glycerol, 1 g poly(dI-dC), and 10 g of bovine serum albumin) for 10 min at room temperature. Similar binding reactions were also performed using 125, 250, and 500 ng of GST and GST-SMAR1 recombinant proteins in binding buffer (as described above) for 15 min at room temperature. Binding complexes and free probe were resolved by 8% native PAGE and processed for autoradiography. Sequences of oligos used for EMSA studies are given in supplemental Table 2 .
Immunoprecipitation-pBK-CMV-SMAR1-transfected or doxorubicin-treated nuclear lysates (200 g) of MCF-7 cells were immunoprecipitated with rabbit ␣-SMAR1 and probed for p65 and p50. Two hundred micrograms of protein was diluted in 1ϫ PBS containing 0.5% Nonidet P-40. Lysates were precleared with control immunoglobulin G (IgG) and 20 l of protein A/G beads for 1 h at 4°C. The precleared lysates were incubated with specific antibody for 12 h and immobilized on protein A/G beads. Beads were washed thrice with 1ϫ PBS containing 0.5% Nonidet P-40 and eluted in 20 l of sample buffer. Endogenous proteins were detected by Western blot analysis.
Chromatin Immunoprecipitation Assays-Chromatin immunoprecipitation (ChIP) assays were performed using a ChIP assay kit (Upstate Biotechnology) following the manufacturer's instructions. Isolated chromatin was immunoprecipitated using respective antibodies as mentioned in the figures. Input DNA, rabbit IgG-, and mouse IgG-pulled DNA served as controls for all the experiments. Immunoprecipitated DNA was then subjected to 25 cycles of PCR using primers for respective promoter regions as mentioned in the figures. Glyceraldehyde-3-phosphate dehydrogenase promoter was used as a nonspecific control for all the ChIP experiments. All primer sequences are given in supplemental Table 1 .
Real Time PCR Array for B Target Genes-MCF-7 cells (5 ϫ 10 6 ) transduced with recombinant SMAR1 adenovirus at a multiplicity of infection of 1:100 or treated with 100 nM SMAR1-specific siRNA for 48 h with or without TNF␣ treatment (10 ng/ml for 2 h) were harvested and subjected to cDNA synthesis following the manufacturer's instructions (Invitrogen). Real time PCR array for NF-B target genes were obtained from Superarray, and array PCR was performed according to the manufacturer's instructions.
RESULTS

Increased NF-B Expression and DNA Binding upon SMAR1
Overexpression-NF-B is activated by a plethora of stimuli including various chemotherapeutic drugs, and it in turn activates transcription of its target genes (1) . Tumor suppressor SMAR1 is down-regulated in breast cancer and is induced by doxorubicin (40) . Because NF-B is also activated by doxorubicin (1), we investigated whether SMAR1 has any correlation with NF-B activity. For this, MCF-7 cells were transiently transfected with SMAR1. Immunoblot analysis revealed increased expression of p65 and p50 subunits of NF-B with increasing doses of SMAR1 (Fig. 1A) . Because in unstimulated normal cells NF-B subunits are localized in cytoplasm in an inactive form bound to a member of the IB protein family, we checked the levels of p65 and p50 subunits in the nuclear and cytoplasmic fractions upon SMAR1 overexpression. Both p65 and p50 subunits were increased in the nuclear fraction of SMAR1-overexpressing MCF-7 cells, whereas the levels in the cytoplasm remained unchanged (Fig. 1B) . Also doxorubicin treatment in MCF-7 cells showed increased expression of p65 as compared with untreated cells (Fig. 1C) . Upon stimulation by various growth factors, cytokines, mitogens, or DNA damage, the p65/p50 subunits rapidly translocate to the nucleus to regulate B target genes through DNA binding. As activation of NF-B subunits results in regulation of different target genes through differences in DNA binding affinity, we investigated the DNA binding of SMAR1-induced NF-B complexes. Electrophoretic mobility shift assay using nuclear lysate from SMAR1-overexpressing cells showed increased DNA binding of p65/p50 heterodimer to the NF-B consensus sequence (22-mer oligo) (Fig. 1D ). An oligo with a mutant NF-B binding site failed to form a complex confirming the specificity of the complex obtained (Fig. 1E) . Further we performed immunofluorescence studies in MCF-7 cell transfected with pEGFPC3 vector and pEGFP-SMAR1. Although overexpression of GFP (green) vector did show any nuclear translocation of p65 that was exclusively localized in the cytosol ( Fig. 2A, upper panel) , overexpression of GFP-SMAR1 (green) resulted in a drastic nuclear translocation as visible by p65 staining (red) (Fig. 2A, lower  panel) . We also observed that p50 was found mostly in the cytosol in GFP-transfected cells (Fig. 2B, upper panel) and translocated into the nucleus of GFP-SMAR1-transfected cells (Fig. 2B, lower panel) . Thus, SMAR1 induces the expression, nuclear accumulation, and DNA binding of p65/p50 subunits to its cognate sequence.
SMAR1 Down-regulates IB␣ Expression-Nuclear translocation of NF-B is tightly regulated by IB␣ that is transcriptionally controlled by NF-B (7, 43) . Cellular stimulation induces the activation of IKK complex. IKK complex phosphorylates members of the IB family (␣, ␤, or ⑀) promoting their rapid ubiquitination and degradation by the proteosome. Interestingly microarray results (data not shown) indicated IB␣ as one of the B target genes affected by SMAR1 (data not shown). This was further validated by real time PCR where 5.8-and 6.2-fold down-regulation of IB␣ transcript was observed upon SMAR1 overexpression and doxorubicin treatment, respectively (Fig. 3, A and B) . Also Western blot analysis showed reduced expression of IB␣ in SMAR1-overexpressing and doxorubicin-treated MCF-7 cells, respectively (Fig. 3, C and D) . We further confirmed the specificity of SMAR1-mediated repression by using SMAR1-specific shRNA. Knockdown of SMAR1 was confirmed by Western blotting (supplemental Fig.  S1 ). MCF-7 cells were transfected with SMAR1-specific shRNA and control shRNA. Twenty-four hours post-transfection doxorubicin (0.2 M) treatment was carried out, and cells were harvested at intervals of 12-36 h to study the expression kinetics of p65, p50, and IB␣. Although doxorubicin treatment resulted in increased SMAR1, p65, and p50 and decreased IB␣ levels in control cells, the expression of p65, p50, and IB␣ remained unchanged upon doxorubicin treatment in SMAR1 shRNA-transfected cells (Fig. 3E ). This suggests that the effect of doxorubicin on p65, p50, and IB␣ expression is SMAR1-dependent. These results indicate that SMAR1 down-regulates IB␣ transcript and that SMAR1 induction is required for doxorubicin-mediated repression of IB␣.
SMAR1 Binds to MAR Present on IB␣ Promoter and Regulates Its
Transcription-MARs are AT-rich cis-acting regulatory elements flanking various promoters and enhancers. SMAR1 has been shown to regulate transcription through binding to MARs (37, 41) . Because our previous results showed that SMAR1 regulates the IB␣ transcript, we investigated possible transcriptional regulation of IB␣ by SMAR1. IB␣ is a well characterized B target gene, and its regulation is critical for NF-B-mediated gene transcription (43) . IB␣ promoter sequence (ϳ1 kb upstream of the transcription start site) was screened for the presence of MARs using MARWIZ (51) . Software analysis predicted a potential 200-bp MAR ϳ376 bp upstream of the distal NF-B binding site (Fig. 4A) . In the next step we performed gel shift assays that demonstrated that purified GST-SMAR1 forms a complex with the 200-bp IB␣-MAR (Probe I) (Fig. 4B) . Further when this 200-bp MAR was reduced to a 50-mer MAR (Probe II) having high AT content, SMAR1 was still able to form a specific complex (Fig. 4C, lanes 2-4) . To check the specificity and the requirement of AT richness for binding of SMAR1, two oligos of the same size were generated by replacing A with G in this 50-mer probe containing the minimal MAR site (Probes III and IV, supplemental Table 2 ) and were checked for SMAR1 binding. Although SMAR1 complex was observed with these probes, the extent of binding was reduced with both Probe III and Probe IV (data not shown) compared with Probe II. However, when the 50-mer Probe II was further shortened to a 35-mer (Probe V) by deleting 15 nucleotides from the 3Ј-end of Probe II, we observed that SMAR1 binding was substantially reduced (Fig. 4D, lanes 2-4) . Based on these results we concluded that the 50-mer MAR is the minimal MAR where SMAR1 binds and might regulate IB␣ transcription. To validate the importance of the MAR in the IB␣ promoter for SMAR1-mediated repression, luciferase reporter assays were performed in MCF-7 cells using fulllength IB␣ promoter. Reporter assays showed that upon TNF␣ treatment there was an ϳ180 times increase in relative luciferase activity of the ⌱〉␣ promoter. However concomitant knockdown of SMAR1 and TNF␣ (8 h) stimulation further increased the relative activity up to ϳ200 times. However, doxorubicin treatment (24 h) and SMAR1 overexpression resulted in decreased promoter activity by about 20 and 40 times, respectively. Further TNF␣ treatment in doxorubicintreated and SMAR1-overexpressing cells did not result in any significant change in the relative luciferase activity (Fig. 4E) . This suggests that SMAR1 antagonizes TNF␣ mediated activation of IB␣. To further establish that the presence of MARs is required for SMAR1-mediated repression, we studied two well known NF-B target genes, namely Bcl-XL and XIAP. The promoters of these genes did not show the presence of MARs (data not shown) as predicted by the MARWIZ software (44) . Western blot analysis in MCF-7 cells transiently transfected with pBK-CMV-SMAR1 in increasing doses did not show any significant change in their protein level (Fig. 4F) . These results confirm that the presence of MARs is critical for SMAR1-mediated transrepression. , PTEN, and p300/ CBP have been reported to regulate post-translational modifications of NF-B that determine the cellular outcome in response to external stimuli (24) . Earlier we have shown that SMAR1 interacts with HDAC1 and brings about transcriptional repression through binding to the MAR element in the Cyclin D1 gene (37) . Interestingly the presence of a 200-bp MAR proximal to the distal NF-B binding site of IB␣ promoter raised the possibility that SMAR1 might cross-talk with NF-B. To check this, we performed an immunoprecipitation assay in MCF-7 cells transiently transfected with pBK-CMV-SMAR1 or treated with doxorubicin. Whole cell extract was pulled down with rabbit polyclonal SMAR1 antibody, and immunoprecipitated complexes were probed with p65 and p50 antibodies. In both cases SMAR1 interacted with p65/p50 heterodimer; however, some endogenous interaction of SMAR1 with p65 was also detected (Fig. 5A ). Further to study recruitment of SMAR1 and other factors at the IB␣ promoter, chromatin immunoprecipitation assays were done. We observed that SMAR1 is recruited to the Probe I region along with p65 and HDAC1. Because the recruitment of HDAC1 is associated with deacetylation of core histones, we checked the status of Histone-3 at lysine 9 at the MAR. As expected, Histone-3 lysine 9 was found to be deacetylated suggesting transcriptional shutdown of IB␣ promoter upon recruitment of SMAR1-HDAC1-p65-p50 to the IB␣ MAR (Fig. 5B) . Thus, SMAR1 mediates the formation of HDAC1-p65-p50 repressor complex at the MAR on IB␣ promoter. Because matrix attachment regions mediate chromatin loop organization and serve as a platform for recruitment of various cofactors to regulate gene expression, the interaction of SMAR1 and p65 at MARs might dictate a specific gene expression profile of NF-B target genes. To further validate whether SMAR1-mediated repression of IB␣ is dependent on its interaction with p65, we used NF-B inhibitor (45) along with doxorubicin treatment. (lanes 1, 3, and 5) . The right panel represents a Western blot for p65, p50, and SMAR1 expression in the above mentioned nuclear lysate (C, control; D, doxorubicin; S, SMAR1 overexpression) shown as input control. B, ChIP assays in pBK-CMV-(denoted as C) and pBK-CMV-SMAR1 (denoted as S)-transfected MCF-7 cells using ␣-SMAR1, ␣-HDAC1, and ␣-acetylated Histone-3 lysine 9 (H3K9) for Probe I region and ␣-p65 and ␣-acetylated Histone-3 lysine 9 for Probe VI region containing all three NF-B sites. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter is used as control. C, ChIP assay in doxorubicin-and NF-B activation inhibitor-treated MCF-7 cells demonstrating the recruitment of SMAR1 onto the IB␣ promoter MAR sequence. Glyceraldehyde-3-phosphate dehydrogenase promoter was used as control. D, Western blot analysis for p65, IB␣, and SMAR1 expression upon treatment with doxorubicin and/or NFB activation inhibitor in MCF-7 cells.
SMAR1 Interacts with p65/p50 Heterodimer and Recruits HDAC1 at IB␣ MAR-NF-B
We found that even in the absence of nuclear p65 SMAR1 can bind to the MAR present in IB␣ promoter (Fig. 5C ). Doxorubicin treatment along with NF-B inhibitor exhibited reduced levels of IB␣ compared with untreated cells. However, SMAR1 expression was unaffected upon addition of NF-B inhibitor (Fig. 5D ). These observations suggest that SMAR1 can bind to the IB␣ promoter MAR in the absence of p65 and can also inhibit IB␣ transcription independently of p65.
SMAR1 Inhibits TNF␣-mediated Activation of NF-B-NF-B is induced by a variety of stimuli either through classical pathways, non-classical pathways, or atypical inducers (1, 9) . TNF␣ is a common proinflammatory cytokine and a typical activator of NF-B, whereas the chemotherapeutic drugs like doxorubicin and daunorubicin fall under the category of nontypical activators (11) . TNF␣-mediated activation of NF-B involves phosphorylation of p65 subunit at Ser-536 that triggers its association with coactivator complex p300/CBP and activation of tumor-promoting genes. However, SMAR1 and its inducer doxorubicin mediated-activation of NF-B and promotes the association of p65 with functional SMAR1-HDAC1 repressor complex. In this context we have shown that SMAR1 and doxorubicin both can inhibit TNF␣-mediated activation of IB␣ reporter gene expression. We therefore investigated the biological effect of SMAR1 on TNF␣-mediated activation of NF-B. For this, MCF-7 cells overexpressing SMAR1 were treated with TNF␣ and probed for p65. Although SMAR1 overexpression and TNF␣ treatment resulted in increased p65 expression independently, TNF␣ treatment in SMAR1-overexpressing cells showed 3-fold reduced activation of p65 as compared with TNF␣ alone (Fig. 6A) . Moreover SMAR1-activated p65/p50 heterodimer was unphosphorylated at the serine 536 residue (Fig. 6B) . Thus, SMAR1-induced NF-B complexes is transactivation-incompetent as unphosphorylated p65 cannot interact with coactivator p300 (20) . Similar results were obtained in confocal analysis. B16F1 SMAR1 stable cells showed 3-fold higher nuclear accumulation of p65 compared with the B16F1 control cells. However, TNF␣ treatment failed to further activate p65 in SMAR1 stable cells (Fig. 6, C and D) . Representative images for the densitometric analysis is given in supplemental Fig. S2 . To further validate whether doxorubicininduced SMAR1 can also antagonize TNF␣-mediated activation of NF-B, MCF-7 cells were treated with TNF␣ alone or in combination with doxorubicin. In the presence of TNF␣, p65 activation followed the typical oscillatory pattern where nuclear p65 was up-regulated during the initial 4 h and came back to the basal level after 8 h. This correlated with IB␣ expression that increased after 8 h. On the other hand, TNF␣ treatment in doxorubicin-treated cells failed to activate p65 in 4 h. Although doxorubicin treatment resulted in p65 activation, the effect was observed 8 h onward with a concomitant increase of SMAR1 and decrease in IB␣ expression. Further the phospho-p65 Ser-536 levels were found to increase only in TNF␣-treated cells but not in TNF␣-and doxorubicin-treated cells (Fig. 6E ). -Fold changes in the expression levels of p65, IB␣, SMAR1, and phospho-p65 upon TNF␣ treatment alone and TNF␣ in combination with doxorubicin is given in supplemental Fig. S3 . Further DNA binding of p65/p50 heterodimer upon TNF␣ treatment was reduced in B16F1 SMAR1 stable cells as compared with the control cells (Fig. 6F) . Mutant NF-B consensus oligo did not show any complex with p65/p50 heterodimer (Fig. 6G) . This suggests that although SMAR1 can activate NF-B through the non-classical pathway it blocks activation of NF-B by typical activators through the classical pathway. This was also supported by data from our microarray analysis where we observed down-modulation of MAPK and ERK signaling pathways, which are indispensable for classical activation of NF-B by TNF␣ (data not shown). Therefore, these results suggest that SMAR1 induced by doxorubicin activates p65 but antagonizes the effect of TNF␣ treatment.
SMAR1 Specifically Represses B Target Genes That Harbor MARsBecause SMAR1 directly represses IB␣ transcription, we further investigated its effect on other B target genes. Real time PCR array for NF-B target genes was performed in MCF-7 cells transduced with recombinant SMAR1 adenovirus or treated with SMAR1 siRNA in the presence or absence of TNF␣. The transcript level of SMAR1 was verified by real time PCR array, which showed about 16-fold upregulation in SMAR1 adenovirustransduced sample and about 9-fold down-regulation in SMAR1 siRNAtreated sample compared with control cells (supplemental Fig. S4B ). SMAR1 expression in recombinant SMAR1 adenovirus-transduced cells is shown as GFP fluorescence (supplemental Fig. S4A ). Real time PCR array in SMAR1 adenovirus-transduced cells showed significant downregulation of a number of B target genes, notably CASP8, IKBKB, JUN, MAP3K1, NFKB1, TBK1, TNFRSF10B (DR5), HPRT1, IRAK, RIPK1, STAT1, RHOA, IL8, IFNG, ATF1, AGT1, CCL2, IL10, and AKT1. Further TNF␣ was not able to induce the expression of these genes in SMAR1-overexpressing MCF-7 cells (Fig. 7A) . Interestingly in SMAR1 siRNA-treated cells, the above mentioned NF-B target genes were induced as compared with the control MCF-7 cells. In addition, TNF␣ increased the expression of these genes in the presence of SMAR1 siRNA (Fig. 7B) . Thus, a reversal in the expression of these genes by SMAR1 siRNA confirmed that SMAR1 directly regulates the transcription of these genes. We further correlated the repression mediated by SMAR1 in 13 genes that have MARs in their promoters. Promoter sequences of 13 B target genes were subjected to MAR analysis that revealed the presence of MAR sequence in all these promoters within a 1-kb vicinity of the NF-B binding sites (Fig. 8A and Table 1 ). Further chromatin immunoprecipitation for AGT1, AKT1, CCL2, IL10, and IFNG promoters showed the presence of SMAR1-p65-HDAC1 repressor complex in vivo upon doxorubicin treatment in MCF-7 cells (Fig. 8B ). These observations suggest that MARs present near the NF-B binding sites play a critical role in regulating the repression mediated by SMAR1. Also our observation suggested that SMAR1-mediated silencing of NF-B target genes is promoter-specific. Thus, our study provides a model showing the effect of SMAR1 on NF-B-mediated transcription wherein SMAR1 facilitates the formation of a silencing complex along with the NF-B transcription factor leading to down-regulation of NF-B-mediated transcription at specific promoters (Fig. 9) . However, the knockdown of SMAR1 leads to up-regulation of those NF-B target genes because of derepression. Therefore, SMAR1 regulates the expression of a subset of B target genes in a promoter-specific manner through MARs.
DISCUSSION
Transcriptional regulation is dependent on chromatin accessibility that is maintained through various cis-elements like scaffold/MARs, locus control regions, silencers, and insulators from where they influence the transcription of associated gene loci (32, 42, 46) . MAR-binding proteins act as transcriptional switches because of their intrinsic ability to interact with both classes of chromatin-modifying enzymes, histone acetyltransferases and HDACs. Mostly MAR-binding proteins act in cohort with various cofactors to regulate transcription. For example proteins like Cux/CCAAT displacement protein and SATB1 exist in a complex with HDACs to bring about gene silencing (47, 48) . Various other repressor proteins like SIN3, Mi2-NURD, and CoREST form complexes with MAR-binding proteins to regulate transcriptional repression (49, 50) . SMAR1 is a DNA-binding protein, and the major mechanism by which it exhibits its repressor function is by recruitment of HDAC1. In agreement with this, we found down-regulation of IB␣ transcript upon SMAR1 overexpression. EMSA studies further proved that SMAR1 directly binds to a MAR site in the IB␣ promoter. Because IB␣ is a major regulator of NF-B, any change in the level of IB␣ by SMAR1 would reflect changes in the way NF-B regulates its wide spectrum of target genes. Furthermore because SMAR1 is a tumor suppressor, IB␣ regulation by SMAR1 could potentially dictate the functionality and role of NF-B in tumorigenesis.
In the present study we demonstrate that SMAR1, another tumor suppressor protein, can regulate NF-B mediated transcription. We show that SMAR1 overexpression or SMAR1 induction by doxorubicin resulted in increased nuclear accumulation of p65 and p50 subunits. Consequently an increased DNA binding of p65/p50 heterodimer to NF-B consensus sequence was observed. Microarray studies done using an overexpression and knockdown approach in MCF-7 cells highlighted a number of NF-B-regulated genes affected by SMAR1 along with IB␣ (data not shown). We chose to study SMAR1-mediated regulation of IB␣, which is a very well documented regulator of NF-B. IB␣ under normal condition binds NF-B and keeps it in the cytoplasm in an inactive form. Phosphorylation and proteolytic degradation of IB␣ by IKK complex in response to activation of various signaling pathways make up the major mechanism known to regulate NF-B-mediated gene regulation (24) . Recently it was reported that recruitment of various corepressors are involved in regulation of IB␣ (51) . However, the direct involvement of any transcription factor that brings about the recruitment of corepressor complexes was not known. In this study we show for the first time that SMAR1 and its inducer doxorubicin directly regulated IB␣ transcription through recruitment of HDAC1 repressor complex. Recent work from Ho et al. (52) showed that doxorubicin induces IB␣ proteolytic degradation both in HEK293 and MDA-MB-231 cells. However, IB␣ regulation has also been reported to occur at the transcript level (53) . Using transient promoter transactivation assays and real time PCR, we found that SMAR1 overexpression and doxorubicin treatment repress IB␣ transcript concomitant with a decrease in the total protein levels. This confirms that SMAR1 regulates IB␣ gene regulation.
NF-B is known to exhibit both tumor-promoting and tumor-inhibiting functions in a context-dependent manner through its association with various coactivators and corepressors (25) . The CBP and p300 coactivators interact with the p65 subunit of NF-B to enhance its transcriptional activity (54) . Phosphorylation of p65 by protein kinase A also stimulates NF-B-dependent gene expression through enhanced p65-CBP interaction (20) . The acetylase activity of PCAF coactivator has also been shown to be required for NF-B-dependent gene activation (55) . Further the SRC-1 coactivator protein was shown to interact with the p50 subunit of NF-B to potentiate transcription from B-containing promoters (56) . Thus, the tumor-pro- moting functions of NF-B have been well documented. Earlier two tumor suppressors, p53 and ARF, were reported to modulate the activity of NF-B in a way that represses rather than activates the expression of various tumor-promoting genes (24) . Differential activation of NF-B subunits can result in the regulation of different subsets of NF-B target genes through their interactions with heterologous DNA-binding proteins. Because both NF-B and the MAR site in the IB␣ promoter lie in close vicinity of each other we investigated whether p65/p50 heterodimer cross-talks with SMAR1 forming a transcriptional complex. We found that SMAR1 interacts with both p65 and p50 subunits of NF-B endogenously as well as when overexpressed and induced by doxorubicin. A chromatin immunoprecipitation assay also showed the recruitment of SMAR1-p65-p50-HDAC1 repressor complex at IB␣ MAR. This correlated with the deacetylation of core Histone-3 and thus resulted in transcriptional repression of IB␣. Similar results were observed with doxorubicin treatment indicating that endogenous SMAR1 can also repress IB␣ expression. Additionally using NF-B inhibitor, we found that even in the absence of NF-B SMAR1 can exert its repressive function through binding to IB␣ MAR. These findings suggest that heterologous DNA binding factors like SMAR1 can induce NF-B to function as a tumor suppressor rather than as an activator. Thus, factors like SMAR1 can act as checkpoint proteins to dictate the functionality of NF-B. However, in advanced breast cancer SMAR1 is reported to be down-modulated (40) . The loss of check point proteins like SMAR1 might actually unleash the oncogenic functions of NF-B by converting it from a tumor suppressor to a tumor inducer. TNF␣ is an important proinflammatory cytokine that promotes tumor cell proliferation, metastasis, and angiogenesis in the tumor microenvironment through activation of NF-B target genes like Cox2, matrix metalloproteinases, and vascular endothelial growth factor. Under these conditions, phosphorylation of p65 by TNF␣ through MAPK and ERK pathways has been shown to be important for its transactivation potential. Also previous reports have shown that atypical activators of NF-B like UV-C irradiation, daunorubicin, and doxorubicin can antagonize activation of NF-B by the classical pathway (57) . Furthermore phosphorylation has not been reported to be important for NF-B activation by atypical activators (52) . In view of this, we found that SMAR1 overexpression inhibited TNF␣-mediated activation of NF-B. Further SMAR1-induced NF-B was also deficient in Rel A phosphorylation at Ser-536 making it transactivation-incompetent. Interestingly SMAR1 overexpression inhibited MAPK and ERK activation pathways as indicated by our microarray data (data not shown). Thus, SMAR1 might hinder the phosphorylation cascade induced by TNF␣ and thereby inhibit p65 activation through the classical pathway.
Targeted real time PCR array for NF-B target genes revealed that a subset of genes was specifically regulated by SMAR1 including IL10, AKT1, CCL2 (MCP1), IFNG, AGT1, IL8, etc. IL10 secretion is elevated in the case of non-Hodgkin lymphoma and helps tumors to escape immunosurveillance (57) . AKT signaling is also involved in promoting tumorigenesis, and drugs targeting phosphoinositide 3-kinase/AKT pathways are used as a potential therapy against various cancers (58, 59) . Angiotensin (AGT1) is expressed in human glioblastoma and enhances cell proliferation and survival and glioblastoma progression (60) . CCL2 (monocyte chemoattractant protein-1) is known to enhance cancer bone metastases and angiogenesis (61) . Thus, SMAR1 down-regulates NF-B target genes that are involved in cell proliferation, cell survival, and tumorigenesis.
Further MAR analysis of all these promoter regions revealed the presence of potential MAR sequences within a 1-kb distance from the NF-B sites (Ref. 50 and Table 1 ). This suggested In the classical pathway, upon activation by TNF␣, IB␣ gets phosphorylated and ubiquitinated resulting in its proteosome-mediated degradation. This allows nuclear translocation of p65/p50 and association with coactivator p300 leading to transcription from B target genes. In the atypical pathway, SMAR1 induction by doxorubicin transcriptionally down-regulates IB␣ allowing nuclear translocation of p65-p50 complex. Additionally upon nuclear translocation, p65/p50 associates with SMAR1-HDAC1 forming a repressor complex. This complex is then recruited to the MAR sites (blue rectangles) of B target genes from where it dictates B-mediated transrepression. Ub, ubiquitin.
that such sequences can cross-talk with NF-B binding sites through looping or enhanceosome formation in the presence of SMAR1 and thus can modulate NF-B transactivation. This kind of regulation has recently been reported for Kit gene (62) . SMAR1 depletion using siRNA resulted in up-regulation of these genes suggesting derepression mediated by SMAR1.
Previously various tumor suppressor proteins such as p53, ARF, ING4, and menin have been reported to modulate NF-B transactivation through different mechanisms (27) (28) (29) 63) . We hypothesize that induction of SMAR1 by DNA damage gives rise to repressive forms of NF-B that can inhibit or repress transactivation of a subset of NF-B target genes involved in tumor growth, angiogenesis, and metastases. As such, gradual loss of SMAR1 expression in high grade breast cancer consequently enhances the tumor-promoting functions of NF-B. Therefore, chemotherapeutic agents or natural products that can activate SMAR1 can serve as an effective therapeutic tool against tumors irrespective of NF-B status.
